Estimating Cost Savings from Early Cancer Diagnosis

Estimating Cost Savings from Early Cancer Diagnosis

We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosi...

Full description

Bibliographic Details
Main Authors: Zura Kakushadze, Rakesh Raghubanshi, Willie Yu
Format: Article
Language:English
Published: MDPI AG 2017-09-01
Series:Data
Subjects:
cancer
costs
incidence
stage
early diagnosis
treatment
data
Online Access:https://www.mdpi.com/2306-5729/2/3/30
Description
Summary:We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence rates. A rough estimate for the U.S. national annual treatment cost-savings from early cancer diagnosis is in 11 digits. Using this estimate and cost-neutrality, we also estimate a rough upper bound on the cost of a routine early cancer screening test.
ISSN:2306-5729

Similar Items